Myriad Genetics Inc
NASDAQ:MYGN
Myriad Genetics Inc
NASDAQ:MYGN
Price:
4.43
USD
1.14%
Market Cap:
$412.9m
Relative Value
The Relative Value of one
MYGN
stock under the Base Case scenario is
19.46
USD.
Compared to the current market price of 4.43 USD,
Myriad Genetics Inc
is
Undervalued by 77%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MYGN
Relative Value
Base Case
19.46
USD
Undervaluation 77%
Multiples Across Competitors
MYGN Competitors Multiples
Myriad Genetics Inc Competitors
Myriad Genetics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
412.4m USD | 0.5 | -1.1 | -15.5 | -4.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.6B USD | 6.8 | 173.9 | 16.8 | 23.8 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.3B USD | 5.7 | 27 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD | 6.2 | 21.6 | 14.6 | 14.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.4B USD | 10.3 | 31.2 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD | 5.8 | 18.4 | 13.8 | 15.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR | 14.3 | 33.5 | 57.3 | 58.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.2B AUD | 3.2 | 16.5 | 11.3 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
